Public Companies
Psyched Wellness Attracts Major Investment
Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff
The post Psyched Wellness Attracts…
Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff sits down with us to discuss the evolution of the stigma towards mushrooms, and the interest in psychedelics. We then transition to a discussion on Psyched Wellness, where we hear about the process of development of CALM, the firms latest product, as well as the recent binding agreement with Gotham Green and My Crew Doses Inc.
Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
Information for this briefing was found via Sedar and the companies mentioned. Canacom Group, the parent company of the Deep Dive, is currently long the equity of Psyched Wellness. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
The post Psyched Wellness Attracts Major Investment appeared first on the deep dive.
psychedelics mushroom cse psyched wellness psyched psyc research
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics7 days agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product